HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MDI 301

induces epidermal thickening; structure in first source

Also Known As:

MDI-301; MDI301

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Varani, James: 4 articles (08/2015 - 11/2003)
2.	Dame, Michael K: 2 articles (08/2015 - 10/2009)
3.	Zhang, Jian: 2 articles (11/2004 - 11/2003)
4.	Allen, Ronald: 1 article (08/2015)
5.	Aslam, Muhammad N: 1 article (08/2015)
6.	Cheng, Jason X: 1 article (08/2015)
7.	Khan, Shazli P: 1 article (08/2015)
8.	Kunkel, Steven L: 1 article (08/2015)
9.	McClintock, Shannon: 1 article (08/2015)
10.	Ouillette, Peter D: 1 article (08/2015)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 11/01/2004 - "The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen-dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) alpha. "
2.	Neoplasms (Cancer) 11/01/2004 - "MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. " 11/01/2004 - "This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARalpha, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy."
3.	Myeloid Leukemia (Leukemia, Myelocytic) 08/01/2015 - "MDI 301, a retinoic acid receptor-α - agonist, suppressed the growth of several human myeloid leukemia cell lines (HL60, NB4, OCI-M2, and K562) in vitro and induced cell-substrate adhesion in conjunction with upregulation of CD11b. " 08/01/2015 - "MDI 301 suppresses myeloid leukemia cell growth in vitro and in vivo without the toxicity associated with all-trans retinoic acid therapy."
4.	Hyperplasia 10/01/2009 - "Epidermal hyperplasia was quantified at various MDI 301 concentrations. "
5.	Erythema 11/01/2003 - "The ability of the synthetic retinoid MDI-301, in which the carboxylic acid of 9- cis-retinoic acid (9-cis-RA) is replaced with an ester linkage, to induce epidermal and dermal thickening and skin irritation (erythema and flaking) in hairless (rhino) mice following its topical application was investigated in comparison with that of 14-all- trans-retinoic acid (14-all-trans-RA) and 9-cis-RA. "

Related Drugs and Biologics

1.	Retinoids
2.	Alitretinoin
3.	Estrogens (Estrogen)
4.	Tretinoin (Retinoic Acid)
5.	Retinoic Acid Receptors (Retinoic Acid Receptor)
6.	Esters
7.	Carboxylic Acids

Related Therapies and Procedures

1.	Therapeutics